相关实验视频

Updated: Jun 15, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

基于新辅助剂的三重治疗肝细胞癌与I/II型门静脉瘤血栓瘤

Guimin Hou¹, Feng Zhang¹, Xielin Feng¹

¹Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, People's Republic of China.

Journal of hepatocellular carcinoma

|August 26, 2024

概括

在肝切除术之前的新辅助疗法可能会减少带有门静脉瘤血栓瘤 (PVTT) 的肝细胞癌 (HCC) 的复发. 这种方法改善了HCC和PVTT患者的生存率,并减少了关键复发因素.

科学领域:

肝胆道手术肝胆道手术
在瘤学瘤学.
翻译医学是一种翻译医学.

背景情况:

肝细胞癌 (HCC) 携带门静脉瘤血栓形成 (PVTT) 是一个手术挑战.
肝切除术为PVTT的HCC提供了生存益处,但高复发率仍然存在.
研究新辅助疗法对于改善这些患者的治疗结果至关重要.

研究的目的:

评估新辅助疗法在减少I/II型PVTT切除性HCC复发中的疗效.
为了比较接受新辅助治疗的患者和单独接受手术的患者之间的短期和长期结果.
为了确定新辅助治疗是否改善PVTTHCC患者的整体存活率和无复发存活率.

主要方法:

对138名可切除HCC和I-II型PVTT患者的回顾性分析.
新辅助剂方案包括铁氨酸激酶抑制剂 (TKI),编程死亡1 (PD-1) 抗体和跨动脉化学栓塞 (TACE).
倾向分数匹配 (PSM) 用于控制混因素并比较结果.

主要成果:

新辅助疗法与PSM后的微血管入侵减少,卫星结节和阿尔法-胎蛋白水平升高有关.
接受新辅助治疗的患者表现出瘤复发率降低和生存时间延长.
多变量分析确定了新辅助疗法作为整体和无复发生存的独立保护因素.

结论:

新辅助治疗对于患有I/II型PVTT的HCC患者来说是一个有希望的策略.
这种方法可以减轻不良的病理特征并改善生存结果.
应考虑在接受肝切除术的PVTT患者中选择HCC患者进行新辅助疗法.

关键词:

这是TACE的税率.这就是TKI.肝细胞癌是肝细胞癌.免疫疗法免疫疗法作为一种新辅助治疗,新辅助治疗.门静脉瘤血栓形成门静脉瘤血栓形成

更多相关视频

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

相关概念视频

Esophageal Varices-II: Clinical Features and Management

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...